From December 10 to 12, the CPHI Middle East 2024 was held at the Riyadh International Convention and Exhibition Center in Saudi Arabia.

As the most comprehensive pharmaceutical event in the Middle East and Africa region, it attracted industry leaders, innovators and decision makers from more than 100 countries, over 400 pharmaceutical companies covering the fields of biopharmaceuticals, APIs and formulations, and more than 30,000 visitors attended the event. The event offers an integrated platform for innovation, collaboration, and market development.

Upstream and Downstream Process System Solutions
Morimatsu offers comprehensive process system solutions that cover upstream culture solution, downstream separation and purification solution, and disposable system solution. These solutions are designed to meet the growing demands for cost control, continuous production, and process flexibility in the pharmaceutical industry.

One-Stop Modular Solutions
Morimatsu Pharmadule provides tailored solutions for global customers, supported by flexible modular design and construction technologies. The one-stop turnkey service ensures seamless project progression, from initial design to final delivery, guaranteeing both efficiency and superior quality.

Additionally, Morimatsu presented innovative solutions in pharmaceutical formulation, laboratory setups, and disposable systems, showcasing the latest advancements and cutting-edge concepts in the industry.

The biopharmaceutical market in the MENA region has experienced robust growth in recent years, driven by population growth, rising medical needs, and strong government policy support. Morimatsu has strategically aligned with these trends, positioning itself to capitalize on future market expansion and supply chain integration.

As the pharmaceutical industry embraces a new era of internationalization, digitalization, and personalization, Morimatsu is committed to continuous innovation. The company will provide more high-quality products and advanced technological solutions, while further strengthening its international presence to build a new global pharmaceutical ecosystem.

About Morimatsu LifeSciences

Morimatsu LifeSciences, one of the key business segments of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), mainly consists of Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and its subsidiaries, which serves the pharmaceuticals, bio-pharmaceutical, cosmetic medicine, FMCG (cosmetics, baby, women & home Care, health care, fabric & home care, food, beverage, nutraceuticals) and other industries, providing customers with "core equipment+value-added services+digital intelligent overall factory solutions and services" ("MVP Solutions&Services"), focusing on core equipment, stainless steel process systems, disposable process systems, consumables, laboratory solutions, digital and modular factory solutions and services. 

As a diversified multinational company, Morimatsu has opened subsidiaries or advanced manufacture plants in China, Japan, Sweden, United States, India, Italy, Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by its global footprint of an efficient and professional team.   

Forward-Looking Statements

The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of "predicted", "believed", "forecast", "planned" and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.

Forward-looking statements are based on our Company management's current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guarantees of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.